Healthcare company Haemonetics Corp. (HAE) reported Monday a slight increase in fourth-quarter profit and provided guidance for fiscal 2010.
The Braintree, Massachusetts-based company's fourth quarter net income marginally increased to $13.94 million or $0.53 per share from $13.79 million or $0.52 per share in the previous year.
During the quarter, the company recorded restructuring costs of $4.36 million. Excluding restructuring charges, net income for the quarter was $16.92 million or $0.65 per share, compared to $15.33 million or $0.58 per share in the prior year.
On average, eight analysts polled by Thomson Reuters expected the company to report earnings of $0.63 per share for the quarter. Analysts' estimates typically exclude special items.
Net revenues for the quarter grew 9.8% to $152.4 million from $138.74 million in the earlier year. Five analysts had a consensus revenue estimate of $150.62 million for the quarter.
Surgical/diagnostics disposables revenue was $88 million, up 22% for the quarter, benefited from sales of the TEG Thrombelastograph Hemostasis Analyzer, which was acquired in November 2007.
Geographically, revenues from United States increased to $73.3 million from $62.73 million in the prior year. International revenues increased to $79.1 million from $76.01 million last year.
Operating expenses increased to $64.01 million from $49.83 million in the prior year. Selling, general and administrative expenses grew to $57.06 million from $44.04 million in the preceding year.
For the full fiscal year, the company's net income increased 14% to $59.3 million or $2.27 per share from $51.98 million or $1.94 per share in the previous year. Non-GAAP net income was $64.02 million or $2.45 per share, compared to $56.22 million or $2.10 per share a year ago.
Yearly net revenues grew 16% to $597.88 million from $516.44 million in the earlier year. Excluding the effects of currency, full year net revenues increased 13%.
Brian Concannon, president and chief executive officer said, "We maintained the momentum of fiscal 2008 with double digit growth and strengthened margins down the P&L, while simultaneously completing business transformation, integrating the TEG business, and expanding our blood management solutions value proposition."
Looking ahead to fiscal 2010, Haemonetics expects earnings in the range of $2.75 to $2.85 per share. The company expects revenue growth of 8% to 11% and operating income growth of 12% to 15% for the year.
Analysts expect the company to earn of $2.80 per share on revenues of $649.11 million for fiscal 2010.
Further, the company expects to generate about $60 million of free cash flow for the year and also said that its Board approved a $40 million share repurchase.
HAE is currently trading at $48.85, down $3.19 or 6.13%, on a volume of 115 thousand shares.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.